Written by: Tammy McClellan, PharmD
Download Here

The purpose of this PQI is to expand on therapy management of ibrutinib (Imbruvica) when used in combination with obinutuzumab (Gazyva).

Continue reading Ibrutinib expansion with Obinutuzumab

Read More

Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute
Download Here

To increase awareness and management of adverse effects related to trifluridine/tipiracil treatment in metastatic colorectal cancer.

Continue reading Trifluridine / Tipiracil for Treatment of Gastric Cancer

Read More

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers
Download HereĀ 

The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib. Continue reading Duvelisib for Chronic Lymphocytic Leukemia and Follicular Lymphoma

Read More

Written by: Eric Dallara, RPh, New England Cancer Specialist
Download Here

Diarrhea is the main toxicity of neratinib (Nerlynx) treatment occurring in 95% of patients in the ExteNET trial on the Neratinib arm in which antidiarrheal prophylaxis was not protocol specified.1 Various prevention and treatment strategies for diarrhea have been studied and will be discussed in this PQI. Continue reading Neratinib Diarrhea Management

Read More

Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology
Download Here

This PQI will review appropriate patient identification and management techniques to ensure optimal benefit from telotristat ethyl (Xermelo) therapy. Continue reading Telotristat ethyl: Carcinoid Syndrome Diarrhea

Read More